Related Experiment Video
Updated: Feb 13, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Targeting BCL-2 in Hematologic Malignancies
1Fox Chase Cancer Center, Philadelphia, PA, USA. Nadia.Khan@fccc.edu.
Abstract:
Resistance to apoptosis is one of the hallmarks of cancer and members of the B-cell lymphoma 2 (BCL-2) family of proteins are central regulators of apoptosis. Many cancers become resistant to chemotherapy and apoptosis by up-regulating BCL-2 and other family members, making these proteins attractive targets for cancer therapy. Venetoclax is an orally administered, small-molecule apoptosis stimulant that targets BCL-2 proteins by acting as a BCL-2 homology domain 3 (BH3) mimetic. The drug is approved in the USA and EU as a monotherapy for the for the treatment of certain patients with chronic lymphocytic leukemia (CLL) and is in phase III clinical development for multiple myeloma (MM), and in phase II or I/II clinical trials for acute myeloid leukemia, and several B-cell malignancies, including diffuse large B-cell lymphoma, Waldenstrom's macroglobulinaemia, follicular lymphoma, and mantle-cell lymphoma.
Insights
Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor, targets cancer
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Resistance to apoptosis is a key feature of cancer.
- The B-cell lymphoma 2 (BCL-2) protein family regulates apoptosis and is often upregulated in cancers, leading to chemotherapy resistance.
- BCL-2 proteins are therefore attractive therapeutic targets for cancer treatment.
Purpose of the Study:
- To describe Venetoclax, a small-molecule inhibitor targeting BCL-2 proteins.
- To highlight Venetoclax's mechanism of action as a BCL-2 homology domain 3 (BH3) mimetic.
- To summarize the clinical development and approved indications of Venetoclax.
Main Methods:
- Venetoclax functions as a BCL-2 homology domain 3 (BH3) mimetic.
- It is an orally administered small molecule.
- Clinical trials assess its efficacy in various hematological malignancies.
Main Results:
- Venetoclax is approved as a monotherapy for certain chronic lymphocytic leukemia (CLL) patients in the USA and EU.
- The drug is in Phase III clinical development for multiple myeloma (MM).
- Phase II or I/II trials are ongoing for acute myeloid leukemia and other B-cell malignancies, including diffuse large B-cell lymphoma, Waldenstrom's macroglobulinaemia, follicular lymphoma, and mantle-cell lymphoma.
Conclusions:
- Venetoclax is an effective apoptosis stimulant targeting BCL-2 proteins.
- Its approved use in CLL and ongoing trials in other hematological cancers demonstrate its therapeutic potential.
- Venetoclax represents a significant advancement in targeting BCL-2-driven cancers.
Related Concept Videos
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
2° Amines to N-Nitrosamines: Reaction with NaNO2
SN2 Reaction: Kinetics
In a chemical reaction, a relationship exists between the concentration of reactants and the rate at which the reaction proceeds. The study to measure this relationship is known as the kinetics of a chemical reaction. Kinetic studies are used to deduce the rate law of a chemical reaction, which provides information about the species involved during the transition state of the rate-determining step. Thus, kinetic studies help to derive the mechanism of a...
SN2 Reaction: Mechanism
The presence of the more electronegative halogen in the substrate creates a polarized carbon-halide bond. The halide pulls the electron cloud generating an electrophilic center at the carbon atom. Thus, the carbon atom carries a partial positive charge while the halide has a...
SN2 Reaction: Transition State
When the nucleophile approaches the electrophilic carbon with its lone pairs, the halide acts as a leaving group and moves away with the electron-pair bonded to the carbon. Dotted partial bonds represent the bonds being formed or broken...
SN2 Reaction: Stereochemistry
If the substrate is an achiral molecule at the α-carbon, the inversion of configuration is not...

